3SBio (STU:83B) Construction In Progress: €181 Mil (As of Dec. 2025)


STU:83B 3SBio Inc STU:83B
90 GF Score
Price €1.90
GF Value €1.49
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio Construction In Progress?

3SBio STU:83B +11.72% 90 Construction In Progress is €181 Mil as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.49 (Modestly Overvalued). The stock has 1 warning sign investors should review.

3SBio's quarterly construction in progress declined from Dec. 2024 (€353 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€181 Mil).

3SBio's annual construction in progress increased from Dec. 2023 (€336 Mil) to Dec. 2024 (€353 Mil) but then declined from Dec. 2024 (€353 Mil) to Dec. 2025 (€181 Mil).

3SBio Construction In Progress Historical Data

* Premium members only.

The historical data trend for 3SBio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio Construction In Progress Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 305.96 368.05 336.46 352.58 181.16

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 336.46 0.00 352.58 0.00 181.16
STU:83B
90GF Score
3SBio Inc STU:83B
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €181 Mil mean?
3SBio (STU:83B) has a Construction In Progress of €181 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on 3SBio and its competitors.
Is 3SBio's Construction In Progress too high?
3SBio's current Construction In Progress is €181 Mil. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Construction In Progress compare to VRTX and REGN?
3SBio's Construction In Progress of €181 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on 3SBio and its competitors. 3SBio's current Construction In Progress is €181 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.49, compared to a current price of €1.90 — trading 27.8% above its estimated fair value. The current Construction In Progress is €181 Mil. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For 3SBio (STU:83B), the current Construction In Progress is €181 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.90 is trading 27.8% above its estimated GF Value™ of €1.49. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for STU:83B:

  • Construction In Progress: €181 Mil
  • GF Value™: €1.49 vs. price of €1.90 (27.8% above fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score

Get the complete analysis for STU:83B

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.90
Price
€1.49
GF Value